{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:46:19Z","timestamp":1789879579535,"version":"4.0.1"},"reference-count":25,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.3892\/mco.2017.1251","type":"journal-article","created":{"date-parts":[[2017,5,8]],"date-time":"2017-05-08T11:23:37Z","timestamp":1494242617000},"page":"963-967","source":"Crossref","is-referenced-by-count":26,"title":["Combination therapy with gemcitabine and nab-paclitaxel for locally advanced unresectable pancreatic cancer"],"prefix":"10.3892","volume":"6","author":[{"given":"Takeshi","family":"Saito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keinosuke","family":"Ishido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihisa","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiichi","family":"Wakiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihito","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Hakamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2017,5,8]]},"reference":[{"key":"key20180107152412_b1-mco-0-0-1251","year":"2014","journal-title":"Statistics and Information Department: Vital statistics 2014. Tokyo: Ministry of Health, Labor and Welfare"},{"key":"key20180107152412_b2-mco-0-0-1251","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"key20180107152412_b3-mco-0-0-1251","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1634\/theoncologist.2012-0435","article-title":"FOLFIRINOX in locally advanced pancreatic cancer: The massachusetts general hospital cancer center experience","volume":"18","author":"Faris","year":"2013","journal-title":"Oncologist"},{"key":"key20180107152412_b4-mco-0-0-1251","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1200\/JCO.2011.37.2532","article-title":"Locally advanced pancreatic cancer: Where should we go from here?","volume":"29","author":"Philip","year":"2011","journal-title":"J Clin Oncol"},{"key":"key20180107152412_b5-mco-0-0-1251","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0140-6736(10)62307-0","article-title":"Pancreatic cancer","volume":"378","author":"Vincent","year":"2011","journal-title":"Lancet"},{"key":"key20180107152412_b6-mco-0-0-1251","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"key20180107152412_b7-mco-0-0-1251","first-page":"22","volume-title":"NCCN clinical practic guideline in oncology: Pancreatic adenocarcinoma","author":"National Comprehensive Cancer Network","year":"2015"},{"key":"key20180107152412_b8-mco-0-0-1251","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"key20180107152412_b9-mco-0-0-1251","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s10120-016-0614-4","article-title":"A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer","volume":"20","author":"Nakayama","year":"2017","journal-title":"Gastric Cancer"},{"key":"key20180107152412_b10-mco-0-0-1251","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20180107152412_b11-mco-0-0-1251","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1200\/JCO.2007.10.8605","article-title":"Phase I\/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer","volume":"26","author":"Rizvi","year":"2008","journal-title":"J Clin Oncol"},{"key":"key20180107152412_b12-mco-0-0-1251","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/bjc.2013.415","article-title":"Stromal disrupting effects of nab-paclitaxel in pancreatic cancer","volume":"109","author":"Alvarez","year":"2013","journal-title":"Br J Cancer"},{"key":"key20180107152412_b13-mco-0-0-1251","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1158\/2159-8290.CD-11-0242","article-title":"nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer","volume":"2","author":"Frese","year":"2012","journal-title":"Cancer Discov"},{"key":"key20180107152412_b14-mco-0-0-1251","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00280-016-2972-3","article-title":"Phase I\/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer","volume":"77","author":"Ueno","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20180107152412_b15-mco-0-0-1251","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1748-717X-7-28","article-title":"Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer","volume":"7","author":"Habermehl","year":"2012","journal-title":"Radiat Oncol"},{"key":"key20180107152412_b16-mco-0-0-1251","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/jso.23921","article-title":"Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability","volume":"111","author":"Nanda","year":"2015","journal-title":"J Surg Oncol"},{"key":"key20180107152412_b17-mco-0-0-1251","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1245\/s10434-014-4225-1","article-title":"Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas","volume":"22","author":"Blazer","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"key20180107152412_b18-mco-0-0-1251","doi-asserted-by":"crossref","first-page":"7461","DOI":"10.3748\/wjg.v19.i42.7461","article-title":"Combined radiochemotherapy in patients with locally advanced pancreatic cancer: A meta-analysis","volume":"19","author":"Chen","year":"2013","journal-title":"World J Gastroenterol"},{"key":"key20180107152412_b19-mco-0-0-1251","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/annonc\/mdn281","article-title":"Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000\u201301 FFCD\/SFRO study","volume":"19","author":"Chauffert","year":"2008","journal-title":"Ann Oncol"},{"key":"key20180107152412_b20-mco-0-0-1251","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1200\/JCO.2011.34.8904","article-title":"Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: An Eastern Cooperative Oncology Group trial","volume":"29","author":"Loehrer","year":"2011","journal-title":"J Clin Oncol"},{"key":"key20180107152412_b21-mco-0-0-1251","first-page":"279","article-title":"Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer?","volume":"8","author":"Kim","year":"2007","journal-title":"JOP"},{"key":"key20180107152412_b22-mco-0-0-1251","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.2005.06.050","article-title":"Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer-a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study","volume":"23","author":"Conroy","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20180107152412_b23-mco-0-0-1251","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1200\/JCO.2012.44.4869","article-title":"Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: Results from the PRODIGE 4\/ACCORD 11 randomized trial","volume":"31","author":"Gourgou-Bourgade","year":"2013","journal-title":"J Clin Oncol"},{"key":"key20180107152412_b24-mco-0-0-1251","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"key20180107152412_b25-mco-0-0-1251","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1007\/s00534-013-0616-0","article-title":"Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments: Results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery","volume":"20","author":"Satoi","year":"2013","journal-title":"J Hepatobiliary Pancreat Sci"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2018,1,7]],"date-time":"2018-01-07T15:24:22Z","timestamp":1515338662000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/mco.2017.1251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,8]]},"references-count":25,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,5,8]]},"published-print":{"date-parts":[[2017,6]]}},"alternative-id":["10.3892\/mco.2017.1251"],"URL":"https:\/\/doi.org\/10.3892\/mco.2017.1251","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"value":"2049-9450","type":"print"},{"value":"2049-9469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,8]]}}}